Serial inflammatory biomarkers of the severity, course and outcome of late onset acute respiratory distress syndrome in critically ill patients with or at risk for the syndrome after new-onset fever

Biomarkers in Medicine

Volumn 9, Issue 6, 2015, Pages 605-616

  Hoeboer, Sandra H ^a,b   Groeneveld, A B Johan ^a   Van Der Heijden, Melanie ^a,b   Oudemans Van Straaten, Heleen M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

acute respiratory distress syndrome; angiopoietin 2; biomarkers; febrile critical illness; prediction; procalcitonin; severity and course

Indexed keywords

ANGIOPOIETIN 2; INTERLEUKIN 6; PENTRAXIN 3; PROADRENOMEDULLIN; PROCALCITONIN; ADRENOMEDULLIN; ANGPT2 PROTEIN, HUMAN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCITONIN; IL6 PROTEIN, HUMAN; PROTEIN PRECURSOR; SERUM AMYLOID P;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; AREA UNDER THE CURVE; ARTICLE; CRITICALLY ILL PATIENT; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FEVER; HUMAN; LONGITUDINAL STUDY; LUNG INJURY SCORE; MAJOR CLINICAL STUDY; MALE; MONITORING; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; LUNG INJURY; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADRENOMEDULLIN; ADULT; AGED; ANGIOPOIETIN-2; BIOMARKERS; C-REACTIVE PROTEIN; CALCITONIN; CRITICAL ILLNESS; FEMALE; FEVER; HUMANS; INTERLEUKIN-6; LUNG INJURY; MALE; MIDDLE AGED; PROTEIN PRECURSORS; RESPIRATORY DISTRESS SYNDROME, ADULT; SERUM AMYLOID P-COMPONENT; SEVERITY OF ILLNESS INDEX;

EID: 84931429097     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.15     Document Type: Article

References (43)

1. Ferguson ND, Frutos-Vivar F, Esteban A, et al. Acute respiratory distress syndrome: underrecognition by clinicians and diagnostic accuracy of three clinical definitions. Crit. Care Med. 33, 2228-2234 (2005
2. Wind J, Versteegt J, Twisk J, et al. Epidemiology of acute lung injury and acute respiratory distress syndrome in The Netherlands: a survey. Respir. Med. 101, 2091-2007 (2098
3. Vincent JL, Sakr Y, Groeneveld J, et al. ARDS of early or late onset: does it make a difference?. Chest 137, 81-87 (2010
4. Tulapurkar ME, Almutairy EA, Shah NG, et al. Febrilerange hyperthermia modifies endothelial and neutrophilic functions to promote extravasation. Am. J. Respir. Cell Mol. Biol. 46, 807-814 (2012
5. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 138, 720-723 (1988
6. The ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. JAMA 307, 2526-2533 (2012
7. Hernu R, Wallet F, Thiolliere F, et al. An attempt to validate the modification of the American-European consensus definition of acute lung injury/acute respiratory distress syndrome by the Berlin definition in a university hospital. Intensive Care Med. 39, 2161-2170 (2013
8. Costa ELV, Amato MBP. The new definition for acute lung injury and acute respiratory distress syndrome: is there room for improvement?. Curr. Opin. Crit. Care 19, 16-23 (2013
9. Groeneveld AB, Raijmakers PG. The 67gallium-Transferrin pulmonary leak index in patients at risk for the acute respiratory distress syndrome. Crit. Care Med. 26, 685-691 (1998
10. Frohlich S, Murphy N, Boylan JF. ARDS: progress unlikely with non-biological definition. Br. J. Anaesth. 111, 696-699 (2013
11. Thille AW, Esteban A, Fernández-Segoviano P, et al. Comparison of the Berlin definition for acute respiratory distress syndrome with autopsy. Am. J. Respir. Crit. Care Med. 187, 761-767 (2013
12. Van der Heijden M, van Nieu W, Amerongen GP, Koolwijk P, van Hinsbergh VWM, Groeneveld ABJ. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 63, 903-909 (2008
13. Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir. Med. 2, 611-620 (2014
14. Agrawal A, Zhuo H, Brady S, et al. Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness from two clinical trials. Am. J. Physiol. Lung Cell Mol. Physiol. 303, L634-L639 (2012
15. Tsantes A, Tsangaris I, Kopterides P, et al. The role of procalcitonin and IL-6 in discriminating between septic and non-septic causes of ALI/ARDS: a prospective observational study. Clin. Chem. Lab. Med. 10, 1-8 (2013
16. Terpstra M, Aman J, van Nieuw Amerongen GP, Groeneveld ABJ. Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-Analysis. Crit. Care Med. 42, 691-700 (2014
17. Parikh SM, Mammoto T, Schultz A, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med. 3, 0356-0370 (2006
18. Calfee CS, Eisner MD, Ware LB, et al. Trauma-Associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit. Care Med. 35, 2243-2250 (2007
19. Gallagher DC, Parikh SM, Balonov K, et al. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 29, 656-661 (2008
20. van der Heijden M, Pickkers P, van Nieuw Amerongen GP, et al. Circulating angiopoietin-2 levels in the course of septic shock: relation with fluid balance pulmonary dysfunction and mortality. Intensive Care Med. 35, 1567-1574 (2009
21. Fremont RD, Koyama T, Calfee CS, et al. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J. Trauma 68, 1121-1127 (2010
22. Calfee CS, Gallagher D, Abbott J, Thompson BT, Matthay MA; NHLBI ARDS Network. Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit. Care Med. 40, 1731-1737 (2012
23. Agrawal A, Matthay MA, Kangelaris KN, et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am. J. Respir. Crit. Care Med. 187, 736-742 (2013
24. Ware LB, Koyama T, Zhao Z, et al. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit. Care 17, R253 (2013
25. He X, Han B, Liu M. Long pentraxin 3 in pulmonary infection and acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 292, L1029-L1049 (2007
26. Mauri T, Coppadoro A, Bellani G, et al. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit. Care Med. 36, 2302-2308 (2008
27. Mauri T, Bellani G, Patroniti N, et al. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med. 36, 621-629 (2010
28. Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107, 1062-1073 (1995
29. Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 111, 1306-1321 (1997
30. Lee YL, Chen W, Chen LY, et al. Systemic and bronchoalveolar cytokines as predictors of in-hospital mortality in severe community-Acquired pneumonia. J. Crit. Care 25, 176.e7-13 (2010
31. Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 137, 288-296 (2010
32. Raymondos K, Martin MU, Schmudlach T, et al. Early alveolar and systemic mediator release in patients at different risks for ARDS after multiple trauma. Injury 43, 189-195 (2012
33. Ware LB, Koyama T, Zhao Z, et al. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit. Care 17, R253 (2013
34. Boussekey N, Leroy O, Georges H, Devos P, dEscrivan T, Guery B. Diagnostic and prognostic values of admission procalcitonin levels in community-Acquired pneumonia in an intensive care unit. Infection 33, 257-263 (2005
35. Tseng JS, Chan MC, Hsu JY, Kuo BI, Wu CL. Procalcitonin is a valuable prognostic marker in ARDS caused by community acquired pneumonia. Respirology 13, 505-509 (2008
36. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-Adrenomedullin as a prognostic marker in sepsis: an observational study. Crit. Care 9, R816-R824 (2005
37. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Proadrenomedullin to predict severity and outcome in community-Acquired pneumonia (ISRCTN04176397). Crit. Care 10, R96 (2006
38. Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in communityacquired pneumonia. Chest 136, 823-831 (2009
39. Courtais C, Kuster N, Dupuy AM, et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am. J. Emerg. Med. 31, 215-221 (2013
40. Hoeboer SH, Alberts E, van den Hul I, Tacx AN, Debets Ossenkopp YJ, Groeneveld ABJ. Old and new biomarkers for predicting high and low risk microbial infection in critically ill patients with new onset fever: a case for procalcitonin. J. Infect. 64, 484-493 (2012
41. Levy MM, Fink MP, Marshall JC, et al. International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/.SIS international sepsis definitions conference. Intensive Care Med. 29, 530-538 (2003
42. Calandra T, Cohen J. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit. Care Med. 33, 1538-1548 (2005
43. Youden WJ. Index for rating diagnostic tests. Cancer 3, 32-35 (1950